Clinical

Interclass biologic switching can improve outcomes, but it also increases infection rates.

New long-term data highlights the effectiveness and safety of ivosidenib plus azacitidine for treating IDH1-mutated acute myeloid leukemia in vulnerable patients.

Zongertinib gains FDA approval for treating HER2-mutated non–small cell lung cancer (NSCLC), offering hope with fewer side effects and promising response rates in patients.

Christina Poh, MD, of City of Hope National Medical Center, highlights the benefit of tafasitamab in improving progression-free survival for heavily pretreated patients with relapsed or refractory (R/R) follicular lymphoma.

The FDA approved multiple groundbreaking treatments in July, enhancing options across patient populations.

Elise S. Tremblay, MD, MPH, discusses her study on trends in insulin out-of-pocket costs and use disparities from 2008 to 2021, highlighting how health plan structure and income level influenced access and adherence.

Bevacizumab combined with chemotherapy was not as effective in advanced driver gene-negative nonsquamous non–small cell lung cancer (NSCLC) compared with immune checkpoint inhibitors plus chemotherapy.

Higher social vulnerability in patients with ovarian cancer leads to longer treatment delays but earlier palliative care consultations, highlighting critical health disparities.

Researchers discovered a significant negative correlation between an individual's oxidative balance score and systemic immune-inflammation index, highlighting the role of antioxidants in reducing inflammation.

Panelists discuss how recent updates from the phase 3 IsKia trial demonstrate that isatuximab combined with carfilzomib, lenalidomide, and dexamethasone improves minimal residual disease negativity rates by approximately 10% at both the 10–5 and 10–6 levels, particularly benefiting high-risk patients.

Panelists discuss how the PERSEUS trial’s subgroup analysis reinforced that sustained minimal residual disease negativity predicts better long-term outcomes and demonstrated the potential for treatment de-escalation at the 2-year mark, while other trials like Advance showed dramatic increases in MRD negativity rates with quadruplet therapy.

There are key steps to take that can ensure equitable access to pegcetacoplan, explained Carla Nester, MD, MSA, FASN, who also highlighted remaining questions on long-term outcomes, safety, and pediatric use.

Investigators discuss how their findings on ovarian cancer mortality trends can guide earlier detection and prevention efforts, while also emphasizing the need for further research.

This approval offers a promising new targeted treatment for patients aged 12 and older with C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN), according to Carla Nester, MD, MSA, FASN, addressing a critical gap left by broad immunosuppressive therapies.

The investigators discuss key factors driving persistent ovarian cancer mortality disparities by age, race, and geography, and propose targeted public health and clinical interventions to address them.

This article presents a systematic review of US health care disparities in biologics access across immunology (ie, rheumatology, dermatology, and gastroenterology) and a call to action.

Researchers at Sylvester Comprehensive Cancer Center reveal how body composition analysis predicts treatment response in diffuse large B-cell lymphoma (DLBCL), enhancing precision medicine strategies.

During the Addressing Cardiovascular Risk and Intervening Early webinar, experts discussed innovative strategies for cardiovascular disease prevention, emphasizing risk assessment, lifestyle changes, and collaborative care to improve patient outcomes.

Large language models (LLMs) such as GPT-3.5 and GPT-4 may offer a solution to the costly and inefficient process of manual clinical trial screening, which is often hindered by the inability of structured electronic health record data to capture all necessary criteria.

In a large fecal immunochemical test-based screening program, high adenoma detection rates lowered interval colorectal cancer (CRC) incidence and mortality, but not CRC-specific survival.

Proceeding with hematopoietic stem cell transplantation (HSCT) is more cost-effective than delaying the procedure in patients with intermediate-risk acute myeloid leukemia (AML).

Obecabtagene autoleucel (obe-cel) is shown to be effective and safe for older adults with relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (ALL), while brexucabtagene autoleucel's (brexu-cel) expansion predicts durable remission.

The decline in ovarian cancer mortality rates after 2003 can be attributed to advances in treatment, precision medicine, improved preventive strategies, and a reduced disease incidence, according to Muhammad Faizan, MBBS.

To mark the 30th anniversary of The American Journal of Managed Care (AJMC), each issue in 2025 includes a special feature: reflections from a thought leader on what has changed—and what has not—over the past 3 decades and what’s next for managed care. The August issue features a conversation with Charles N. (Chip) Kahn III, MPH, the president and CEO of the Federation of American Hospitals and a longtime member of the AJMC editorial board.

Following the FDA approval of linvoseltamab (Lynozyfic; Regeneron) for heavily pretreated multiple myeloma, Sundar Jagannath, MBBS, highlights its potential for earlier use, increased accessibility, and greater competition in the B-cell maturation antigen (BCMA) bispecific antibody space.

US ovarian cancer mortality declined from 1999 to 2020, but significant disparities remain among older women, non-Hispanic White women, and those living in rural areas, as well as in the Northeastern and Midwestern regions, according to Muhammad Faizan, MBBS.

Noting the profound impact of living with a chronic condition that constantly reminds patients of their "patient" status, Andrew Kuykendall, MD, Moffitt Cancer Center, emphasizes the importance of therapies that can offer a sense of normalcy.

The newly FDA-approved linvoseltamab (Lynozyfic; Regeneron) may improve access to multiple myeloma treatment by offering an off-the-shelf, outpatient option that can be administered in community settings, according to Sundar Jagannath, MBBS.

Panelists discuss how emerging evidence from first-line therapy trials continues to demonstrate the superiority of quadruplet over triplet regimens, with the CEPHEUS subgroup analysis confirming that even higher-risk and less-fit patients can benefit from 4-drug combinations while maintaining acceptable safety profiles.

Panelists discuss how quality of life (QOL) and treatment convenience should be balanced with maximal depth of response through personalized therapy approaches, emphasizing the importance of multidisciplinary care teams and the flexibility to adapt treatment regimens based on individual patient preferences and circumstances.